EICHOR
● Completed
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
Condition: Parkinson Disease · Sponsor: Integrative Research Laboratories AB
About this study
This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (37)
| Hôpital Neurologique Pierre Wertheimer | Bron, France | — |
| Hopital de la Timone | Marseille, France | — |
| Hôpital Laennec - Centre d'investigation clinique de Neurologie | Nantes, France | — |
| CHU Charles Nicolle | Rouen, France | — |
| CHU Toulouse - Hôpital Purpan | Toulouse, France | — |
| Charite Universitatsmedizin Berlin - Klinik fuer neurologie mit experimenteller neurologie | Berlin, Germany | — |
| Praxis Dr.med. Christian Oehlwein Facharzt für Neurologie und Psychiatrie | Gera, Germany | — |
| Universitätsmedizin Göttingen - Klinik für Neurologie | Göttingen, Germany | — |
| Klinische Forschung Hamburg GmbH | Hamburg, Germany | — |
| Universitaetsklinikum Leipzig - Klinik und Poliklinik fuer Neurologie | Leipzig, Germany | — |
| Philipps-Universitaet Marburg | Marburg, Germany | — |
| Kliniken Kreis Muehldorf a. Inn | Mühldorf, Germany | — |
+ 25 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05258071